# US 2004/0204672 A1 · Catheter and method for the delivery of therapeutic agents to tissues

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0204672 A1
- Document ID: US20040204672A1
- Status: Published application
- Kind: A1
- Application number: 10/837,612
- Filed: 2004-05-04
- Published: 2004-10-14
- Earliest claimed: 2000-03-01
- Assignees: Boston Scientific Scimed, Inc.
- Inventors: Maria Palasis; James J. Barry; Louis Ellis; Gary L. Hendrickson; Kent D. Harrison; Lixiao Wang
- Web page: https://patentgrep.com/patent/US20040204672A1

## CPC

- A61B 17/3468: {for implanting or removing devices, e.g. prostheses, implants, seeds, wires (devices for implanting seeds A61M37/0069)}
- A61B 17/3478: {Endoscopic needles, e.g. for infusion (biopsy needles A61B10/0233; catheters with injection needles A61M25/0067)}
- A61F 2/2493: {Transmyocardial revascularisation [TMR] devices}
- A61L 29/16: Biologically active materials, e.g. therapeutic substances {(A61L29/048 takes precedence)}
- A61M 25/0084: {being one or more injection needles}
- A61M 37/0069: {Devices for implanting pellets, e.g. markers or solid medicaments (for introducing of radioactive sources for interstitial radiation therapy, i.e. brachytherapy A61N5/1027)}
- A61B 90/39: {Markers, e.g. radio-opaque or breast lesions markers}
- A61B 2017/00247: {Making holes in the wall of the heart, e.g. laser Myocardial revascularization}
- A61B 2017/320084: {Irrigation sleeves}
- A61B 2018/00392: {Transmyocardial revascularisation}
- A61B 2018/1425: {Needle}
- A61L 2300/258: Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
- A61L 2300/414: Growth factors
- A61L 2300/64: Animal cells
- A61M 2025/0004: {having two or more concentrically arranged tubes for forming a concentric catheter system}
- A61M 2025/0089: {Single injection needle protruding axially, i.e. along the longitudinal axis of the catheter, from the distal tip}
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}

## Abstract

A method for delivering a therapeutic implant to a tissue is provided. This method includes providing an elongate catheter having a distal end including a lumen, providing a carrier including a therapeutic agent, placing the carrier including the therapeutic agent into the lumen, advancing the distal end of the catheter to the tissue, and depositing the carrier including the therapeutic agent into the tissue.

## Claims

### Claim 1

A method for delivering a therapeutic implant to a tissue comprising:
providing an elongate catheter having a distal end including a lumen;
providing a carrier including a therapeutic agent,
placing the carrier including the therapeutic agent into the lumen;
advancing the distal end of the catheter to the tissue, and
depositing the carrier including the therapeutic agent into the tissue.

### Claim 2 (depends on 1)

The method in accordance with claim 1, wherein the tissue to be treated is ischemic heart tissue.

### Claim 3

The method in accordance with clam 2, wherein the therapeutic agent is selected from the group consisting of VEGF, FGF, PDGF, estrogen, HIF1-α, Akt, DEL-1, angiopoietins and combinations thereof

### Claim 4 (depends on 2)

The method in accordance with claim 2, wherein the therapeutic agent includes genes effecting the production of growth factors.

### Claim 5 (depends on 2)

The method in accordance with claim 2, wherein the therapeutic agent includes genetically engineered cells.

### Claim 6 (depends on 2)

The method in accordance with claim 2, wherein the therapeutic agent includes healthy tissue.

### Claim 7 (depends on 2)

The method in accordance with claim 2, wherein the therapeutic agent includes cells.

### Claim 8 (depends on 1)

The method in accordance with claim 1, wherein the tissue includes failing heart tissue.

### Claim 9 (depends on 8)

The method in accordance with claim 8, wherein the therapeutic agents are selected from the group consisting of positive inotripic, diuretics vasodilators, neurohormonal antagonists, calcium channel blockers, anti-ischemic agents, anti-arrhythmics, anticoagulants, natiruretic peptides, growth hormones, and adenosine receptor antagonists and combination thereof.

### Claim 10 (depends on 1)

The method in accordance with claim 1, wherein the tissue includes heart tissue following myocardial infarction.

### Claim 11 (depends on 10)

The method in accordance with claim 10, wherein the therapeutic agents are selected from the agents consisting of AKT kinases, adenylyl cylase VI, angiogenisis inducing agents and combinations thereof.

### Claim 12 (depends on 1)

The method in accordance with claim 1, wherein the tissue to be treated includes cancerous tissue.

### Claim 13 (depends on 12)

The method in accordance with claim 12, wherein the therapeutic agents are selected from the group consisting of cytoxic proteins, cytostatic agents, genes, anti-angiogenic molecules and combinations thereof.

### Claim 14

A catheter for placement of an in situ implant, comprising:
an elongate shaft having a proximal end and a distal end, the shaft defining a first and a second lumen therethrough;
a first sharpened distal tip disposed at the distal end of the shaft, the first distal tip defining a lumen therethrough in fluid communication with the first lumen; and
a second sharpened distal tip disposed at the distal end of the shaft, the second distal tip defining a lumen in fluid communication with the second lumen.

### Claim 15 (depends on 14)

The catheter of claim 14, further comprising a polymer mixed with a therapeutic agent is disposed in the first lumen.

### Claim 16 (depends on 14)

The catheter of claim 14, further comprising a cross-linking agent disposed in the second lumen.
